Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the alpha-glucosidase inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes. METHODS: We conducted a prospective, randomized, open-label, multicenter study of 100 diabetic patients with LV diastolic dysfunction. Patients received sitagliptin (50 mg/day) or voglibose (0.6 mg/day). The primary endpoints were changes in the e' velocity and E/e' ratio from baseline to 24 weeks later. The secondary efficacy measures included HbA1c, GLP-1, lipid profiles, oxidative stress markers and inflammatory markers. RESULTS: The study was completed with 40 patients in the sitagliptin group and 40 patients in the voglibose group. There were no significant changes in the e' velocity and E/e' ratio from baseline to 24 weeks later in both groups. However, analysis of covariance demonstrated that pioglitazone use is an independent factor associated with changes in the e' and E/e' ratio. Among patients not using pioglitazone, e' increased and the E/e' ratio decreased in both the sitagliptin and voglibose groups. GLP-1 level increased from baseline to 24 weeks later only in the sitagliptin group (4.8 ± 4.7 vs. 7.3 ± 5.5 pmol/L, p < 0.05). The reductions in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group (-0.7 ± 0.6 % vs. -0.3 ± 0.4, p < 0.005; -1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p < 0.05, respectively). There were no changes in lipid profiles and inflammatory markers in both groups. CONCLUSIONS: Our trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with diabetes. TRIAL REGISTRATION: Registered at http://www.umin.ac.jp under UMIN000003784.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Recent studies have shown that dipeptidyl peptidase-4 inhibitor (DPP-4i), which increases the circulating glucagonlike peptide-1 (GLP-1) level, attenuates postprandial hyperglycemia and may have cardio-protective effects [12–14].”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Recently, the SAVOR-TIMI 53 trial showed that DPP4i may increase the risk of HF [25], which is of concern.”
MethodRole of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Diabetic Cardiomyopathy Revisited
Boudina, S., & Abel, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.679597 · Cited by 1,543
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Small pilot studies of GLP-1 have shown potential promise in the treatment of HF patients [17, 18].”
BackgroundThe Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812
Boyer, J. K., Thanigaraj, S., Schechtman, K. B., & Pérez, J. E. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.026 · Cited by 534 · cited 1×
“Background Diabetes mellitus is a major risk factor for heart failure (HF), especially HF with preserved ejection fraction (HFPEF) development [1, 2].”
BackgroundShekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00262-6 · Cited by 492 · cited 1×
“An angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) is effective in treating HF as well as reducing insulin resistance in patients with diabetes [9].”
BackgroundDiabetes in heart failure: prevalence and impact on outcome in the population
From, A. M., Leibson, C. L., Bursi, F., Redfield, M. M., Weston, S. A., Jacobsen, S. J., Rodeheffer, R. J., & Roger, V. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.024 · Cited by 295 · cited 1×
“8 % per year) [8].”
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 1×
“Increased GLP-1 may augment diuresis and natriuresis by inhibiting sodium reabsorption from the proximal renal tubule [31].”
Background
Research works printed but not linked: 27
- Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy. Fact or fiction? Herz. 2011;36:102–15. · DOI · Paper page
- Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595–602. · DOI · Paper page
- Aguilar D. Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardiovasc Med. 2008;10:465–75. · DOI
- Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study. Lancet. 2011;378:140–6. · DOI · Paper page
- Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73. · DOI · Paper page
- Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81–99. · DOI · Paper page
- Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187–215. · DOI · Paper page
- Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012;126:1838–51. · DOI · Paper page
- dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail. 2013;6:1029–38. · DOI · Paper page
- Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern Jr GJ, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–9. · DOI · Paper page
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63. · DOI · Paper page
- Von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res. 2008;5:310–8. · DOI
- Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85. · DOI · Paper page
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. · DOI · Paper page
- Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, The Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. · DOI · Paper page
- Patel A, MacMahon S, Chalmers J, Neal B, Billot L, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. · DOI · Paper page
- Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-γ–mediated effects in the vasculature. Circ Res. 2008;102:283–94. · DOI · Paper page
- Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. American heart association; thiazolidinedione Use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–8. · DOI · Paper page
- Ravassa S, Barba J, Coma-Canella I, Huerta A, López B, González A, et al. The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:143. · DOI
- Fukuta H, Ohte N, Wakami K, Goto T, Tani T, Kimura G. Relation of plasma levels of adiponectin to left ventricular diastolic dysfunction in patients undergoing cardiac catheterization for coronary artery disease. Am J Cardiol. 2011;108:1081–5. · DOI
- Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, et al. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus–a randomized controlled trial START-J study. Cardiovasc Diabetol. 2014;13:96. · DOI
- Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59:265–76. · DOI · Paper page
- Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens. 2012;6:163–8. · DOI
- Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Valsartan In Diastolic Dysfunction (VALIDD) investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomized trial. Lancet. 2007;369:2079–87. · DOI · Paper page
- Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol. 2014;13:43. · DOI
- Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7. · DOI · Paper page
- Frikha Z, Girerd N, Huttin O, Courand PY, Bozec E, Olivier A, et al. Reproducibility in Echocardiographic Assessment of Diastolic Function in a Population Based Study (The STANISLAS Cohort Study). PLoS One. 2015;10:e0122336. · DOI
Cited by
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073587 · Cited by 268
Self-citationTian, Y., Chen, T., Wu, Y., Yang, L., Wang, L., Fan, X., Zhang, W., Feng, J., Yu, H., Yang, Y., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0623-6 · Cited by 66
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021) · Revista de Investigación Clínica · doi:10.24875/ric.20000308 · Cited by 6
Metadata
- Authors
- FESC, F. E. O. A. D.-4. I. O. L. V. D. D. I. P. W. T. 2. D. A. D. C. (. S. I., Oe, H., Nakamura, K., Kihara, H., Shimada, K., Fukuda, S., Takagi, T., Miyoshi, T., Hirata, K., Yoshikawa, J., & Ito, H.
- Venue
- Cardiovascular Diabetology
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 1
- Pages
- 83-83
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W1582267185
- Cited by
- 63
- References
- 10
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. https://app.cochat.ai/papers/10.1186/s12933-015-0242-z
- The paper
- FESC, F. E. O. A. D.-4. I. O. L. V. D. D. I. P. W. T. 2. D. A. D. C. (. S. I., Oe, H., Nakamura, K., Kihara, H., Shimada, K., Fukuda, S., Takagi, T., Miyoshi, T., Hirata, K., Yoshikawa, J., & Ito, H. (2015). Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-015-0242-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.